Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia

[1]  M. Inglese,et al.  Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic , 2022, Neurotherapeutics.

[2]  A. Risedal,et al.  Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial , 2022, The Lancet Neurology.

[3]  E. Leray,et al.  Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal , 2022, Neurotherapeutics.

[4]  Mohammad Hossein Morowvat,et al.  Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis , 2022, BMC Health Services Research.

[5]  L. Kremer,et al.  Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study , 2022, Journal of Neurology.

[6]  Nuha M. Alkhawajah,et al.  Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia , 2021, International Journal of Environmental Research and Public Health.

[7]  T. Cai,et al.  Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis , 2021, JAMA network open.

[8]  C. Pozzilli,et al.  Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[9]  F. Zipp,et al.  Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19 , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[10]  F. Barkhof,et al.  Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients , 2021, Multiple sclerosis journal - experimental, translational and clinical.

[11]  A. Gallo,et al.  Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study , 2021, Neurotherapeutics.

[12]  A. Rae-Grant,et al.  Diagnosis and Treatment of Multiple Sclerosis: A Review. , 2021, JAMA.

[13]  F. Patti,et al.  Rituximab for the treatment of multiple sclerosis: a review , 2021, Journal of Neurology.

[14]  E. Leray,et al.  Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition , 2020, Multiple sclerosis.

[15]  Claudio Conversano,et al.  On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers , 2020, Frontiers in Public Health.

[16]  Y. AlRuthia,et al.  COVID-19 and Saudi Arabia public financing of prescription drugs: An opportunity for reform , 2020 .

[17]  T. Vollmer,et al.  Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment , 2020, Annals of clinical and translational neurology.

[18]  S. Hauser,et al.  Treatment of Multiple Sclerosis: A Review. , 2020, The American journal of medicine.

[19]  H. Ford.  Clinical presentation and diagnosis of multiple sclerosis. , 2020, Clinical medicine.

[20]  R. Trimble.  COVID-19 Dashboard , 2020 .

[21]  R. Bunyan,et al.  Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study , 2019, BMC Neurology.

[22]  Robert C Reiner,et al.  Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[23]  E. D’Amico,et al.  Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. , 2019, Multiple sclerosis and related disorders.

[24]  Richard A. Parker,et al.  Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis , 2018, BMJ Open.

[25]  F. Piehl,et al.  Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry , 2018, Multiple sclerosis.

[26]  B. Uitdehaag.  Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis , 2018, CNS Drugs.

[27]  S. Razavi,et al.  Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy , 2016, Cell journal.

[28]  P. Vermersch,et al.  Comparative efficacy of fingolimod vs natalizumab , 2016, Neurology.

[29]  G. Saposnik,et al.  Decision making under uncertainty, therapeutic inertia, and physicians’ risk preferences in the management of multiple sclerosis (DIScUTIR MS) , 2016, BMC Neurology.

[30]  L. Kappos,et al.  Comparative efficacy of first-line natalizumab vs IFN-&bgr; or glatiramer acetate in relapsing MS , 2016, Neurology. Clinical practice.

[31]  M. Benedetti,et al.  Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? , 2015, World journal of clinical cases.

[32]  G. Capkun,et al.  Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study , 2014, PloS one.

[33]  M. Daumer,et al.  Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach: Measuring disability in relapsing-remitting MS , 2011, Neurology.

[34]  M. Jhaveri,et al.  All-Cause Health Care Utilization and Costs Associated with Newly Diagnosed Multiple Sclerosis in the United States , 2010, Journal of managed care pharmacy : JMCP.

[35]  L. Roccatagliata,et al.  Surrogate endpoints for EDSS worsening in multiple sclerosis , 2010, Neurology.

[36]  Karl Claxton,et al.  Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. , 2009, Health policy.

[37]  P Speck,et al.  Global perspectives , 1999, Palliative medicine.

[38]  T. Fog,et al.  [Multiple sclerosis; review]. , 1954, Maanedsskrift for praktisk laegegerning og social Medicin.

[39]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.